Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: April 7, 2011
Last updated: June 27, 2014
Last verified: June 2014

Pregabalin has proven effective in previous clinical trails in other countries in relieving neuropathic pain associated with postherpetic neuralgia and painful diabetic neuropathy.

This study is being conducted according to China registration requirement to submit a reapplication with new local diabetic peripheral neuropathy study as a commitment plus the existing data to apply for Lyrica "pain associated with postherpetic neuralgia" indication after Lyrica "pain associated with postherpetic neuralgia" is approved.

Condition Intervention Phase
Diabetic Neuropathy, Painful
Drug: Pregabalin
Drug: Placebo matched with pregabalin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: An 11-week Randomized, Double-blind, Multi Center, Placebo-Controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (300 Mg/Day) Using A Fixed Dosing Schedule In The Treatment Of Subjects With Pain Associated With Diabetic Peripheral Neuropathy.

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Endpoint mean pain score based on the pain scores from the subject's daily pain rating scale [ Time Frame: From baseline to week 9 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Weekly mean pain scores from the subject's daily pain rating scale [ Time Frame: End of week 1, 2, 3, 4, 5, 6, 7, 8, 9 ] [ Designated as safety issue: No ]
  • Weekly mean sleep interference scores from the subject's daily sleep interference scale [ Time Frame: End of week 1, 2, 3, 4, 5, 6, 7, 8, 9 ] [ Designated as safety issue: No ]
  • Responder rates with at least a 30% reduction from baseline in weekly mean pain score [ Time Frame: From baseline to week 9 ] [ Designated as safety issue: No ]
  • Change from baseline in Short-Form McGill Pain Questionnaire at week 9 [ Time Frame: From baseline to week 9 ] [ Designated as safety issue: No ]
  • Change from baseline in Pain Visual Analogue Scale at week 9 [ Time Frame: From baseline to week 9 ] [ Designated as safety issue: No ]
  • Change from baseline in Medical Outcomes Study -Sleep Scale at week 9 [ Time Frame: From baseline to week 9 ] [ Designated as safety issue: No ]
  • The Subject Global Impression of Change at week 9 [ Time Frame: From baseline to week 9 ] [ Designated as safety issue: No ]
  • The Clinical Global Impression of Change at week 9 [ Time Frame: From baseline to week 9 ] [ Designated as safety issue: No ]
  • Change from baseline in Hospital Anxiety and Depression Scale at week 9 [ Time Frame: From baseline to week 9 ] [ Designated as safety issue: No ]

Enrollment: 626
Study Start Date: July 2011
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 300 mg/day pregabalin (Lyrica)
Patient take pregabalin capsule twice a day
Drug: Pregabalin

Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn.

At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day.

Placebo Comparator: Placebo Drug: Placebo matched with pregabalin
Subject will take placebo matched with pregabalin twice a day.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female subjects aged 18 years or older
  • Diagnosis of painful, distal, symmetrical, sensorimotor polyneuropathy which is due to diabetes mellitus (Type 1 or 2), and symptoms of painful diabetic neuropathy for 6 months to 5 years (inclusive).
  • At the baseline and randomization visits, a score of ≥50 mm on the Visual Analogue Scale, at randomization, subjects must have completed at least 5 daily pain interference diaries, and have an average daily pain score of ≥5 over the past 7 days.
  • Patient who are willing and capable to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Women of childbearing potential are willing to use contraception during study.

Exclusion Criteria:

  • Subjects with more than 30% decrease on the Pain Visual Analog Scale at randomization as compared to screening; and during the 1 week screening period, with more than one pain score <3 in pain scores.
  • Subject has other kinds of neurological disorder, pain of other reason, or skin condition that could confuse the assessment.
  • Subject with any other serious or unstable condition which in the opinion of the investigator might compromise participation in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01332149

  Hide Study Locations
China, Beijing
The second artillery general hospital of PLA
Beijing, Beijing, China, 100088
China, Chongqing
Southwest hospital of the third military medical university/Department of Neurology
Chongqing, Chongqing, China, 400038
China, Fujian
Fuzhou General Hospital of Nanjing Military Command
Fuzhou, Fujian, China, 350025
China, Guangdong
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510260
Department of Endocrinology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China, 510120
China, Heilongjiang
Dept. of Endocrinology, The first Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China, 150001
Dept. of Endocrinology, The second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China, 150086
China, Hubei
Tongji Hospital,Tongji Medical College Huazhong University of Science & Technology
Wuhan, Hubei, China, 430030
China, Hunan
Xiangya Hospital of Centre-south University
Changsha, Hunan, China, 410008
China, Jiangsu
Jiangsu Province Hospital
Nanjing, Jiangsu, China, 210029
China, Jiangxi
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China, 330006
China, Jilin
Dept. of Endocrinology, The second hospital of Jilin University
Changchun, Jilin, China, 130041
China, Liaoning
Shengjing hospital of china medical university
Shenyang, Liaoning, China, 110004
China, Shandong
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250012
Qilu Hospital of Shandong University/department of internal neurology
Jinan, Shandong, China, 250012
China, Shanxi
First Hospital of Shanxi Medical University
Taiyuan City, Shanxi, China, 030001
China, Tianjin
Tianjin Medical University General Hospital
Tianjin, Tianjin, China, 300052
China, Zhejiang
Sir Run Run Shaw Hospital, School of medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310016
The Second Affiliated Hospital Zhejiang University College of Medicine
Hangzhou, Zhejiang, China, 310009
Chinese PLA General Hospital
Beijing, China, 100853
Beijing Tiantan Hospital affiliated to Capital Medical University, Neurology Department
Beijing, China, 100050
Tongren Hospital Affiliated to Capital Medical University
Beijing, China, 100730
Endocrinology Department
Beijing, China, 100700
Beijing Hospital of the Ministry of Health
Beijing, China, 100730
Peking University Third Hospital
Beijing, China, 100191
GuangZhou First Municipal People's Hospital
Guangzhou, China, 510180
Huashan Hospital Affiliated Fudan University, Neurology Department
Shang Hai, China, 200040
Renji Hospital Shanghai Jiao Tong University School of Medicine/Neurology Department
Shanghai, China, 200127
Shanghai Changzheng Hospital
Shanghai, China, 200003
Shanghai First People's Hospital
Shanghai, China, 200080
Shanghai Tenth People's Hospital/The Endocrinology Department
Shanghai, China, 200072
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer Identifier: NCT01332149     History of Changes
Other Study ID Numbers: A0081265
Study First Received: April 7, 2011
Last Updated: June 27, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Diabetic Neuropathies
Efficacy of pregabalin
Placebo controlled

Additional relevant MeSH terms:
Diabetic Neuropathies
Peripheral Nervous System Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Nervous System Diseases
Neuromuscular Diseases
Gamma-Aminobutyric Acid
Calcium Channel Blockers
Cardiovascular Agents
Central Nervous System Agents
GABA Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on May 21, 2015